HC Wainwright Expects Lower Earnings for Delcath Systems

Delcath Systems, Inc. (NASDAQ:DCTH) – HC Wainwright reduced their Q2 2027 earnings estimates for shares of Delcath Systems in a research note issued on Tuesday, November 10th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $0.11 per share for the quarter, down from their prior forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Delcath Systems’ FY2028 earnings at $0.68 EPS, FY2029 earnings at $1.08 EPS and FY2030 earnings at $1.61 EPS.

DCTH has been the subject of several other research reports. Weiss Ratings lowered shares of Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Wall Street Zen upgraded shares of Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Zacks Research cut shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Finally, BTIG Research increased their price target on Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a report on Monday. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Delcath Systems presently has an average rating of “Moderate Buy” and an average target price of $29.33.

Delcath Systems Stock Performance

DCTH opened at $20.10 on Wednesday. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $21.84. The firm has a 50 day moving average price of $15.60 and a 200 day moving average price of $12.54. The company has a market cap of $697.47 million, a PE ratio of 125.62 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Monday, November 9th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.26. The business had revenue of $35.10 million during the quarter, compared to the consensus estimate of $25.99 million. Delcath Systems had a return on equity of 5.78% and a net margin of 6.05%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in Delcath Systems by 31.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after buying an additional 21,069 shares during the period. Alps Advisors Inc. grew its stake in shares of Delcath Systems by 30.3% during the third quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock valued at $729,000 after acquiring an additional 10,600 shares in the last quarter. Kopp Family Office LLC acquired a new stake in shares of Delcath Systems during the third quarter valued at about $450,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Delcath Systems during the second quarter worth about $48,000. Finally, IFP Advisors Inc purchased a new stake in shares of Delcath Systems during the second quarter worth about $52,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Delcath reported quarterly EPS of $0.17, versus analysts’ consensus estimate of a $0.09 loss, and revenue of $35.1 million, well above the $26.0 million expected. The company also raised its 2026 revenue outlook to $115 million–$117 million, compared with consensus of $106.2 million. Earnings report
• Positive Sentiment: HC Wainwright reiterated its Buy rating and lifted its price target from $32 to $36. It also raised its EPS forecasts for 2028, 2029 and 2030 to $0.68, $1.08 and $1.61, respectively. The stock recently reached a new 12-month high following the earnings news. Delcath reaches a 12-month high
• Negative Sentiment: HC Wainwright lowered its Q2 2027 EPS estimate slightly, to $0.11 from $0.12. This modest near-term reduction contrasts with its higher longer-term forecasts. HC Wainwright research

Delcath Systems Company Profile

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.